

Special Issue

Immunobiology of *Mycobacterium tuberculosis* and Its Implication in Vaccine Design

Message from the Guest Editors

The aim of this Special Issue is to bring together reviews, commentaries, and research articles in the areas of TB immunity that can help drive better vaccine design and vaccination approaches to control or eradicate Mtb. We invite authors to submit work that they view as relevant to these goals, including, but not limited to, the following topics:

- Intravenous BCG and other nontraditional routes of vaccine administration.
- Newly recognized TB antigens, including subdominant and cryptic antigens or antigenic decoys.
- Adjuvant formulations.
- Eradicating dormant and persistent forms of Mtb.
- Prime-boost vaccination with attenuated Mtb or BCG strains.
- Mycobacterium-specific T and B cell responses.

We look forward to receiving your contributions to inspire the TB research community to help eradicate this deadly disease. Dr. Tony W. Ng

Guest Editors

Dr. Tony W. Ng

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Prof. Dr. Steven A. Porcelli

Department of Microbiology and Immunology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA

Deadline for manuscript submissions

1 November 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/213527

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).